These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

608 related articles for article (PubMed ID: 28789523)

  • 1. Efficient siRNA Delivery by Lipid Nanoparticles Modified with a Nonstandard Macrocyclic Peptide for EpCAM-Targeting.
    Sakurai Y; Mizumura W; Murata M; Hada T; Yamamoto S; Ito K; Iwasaki K; Katoh T; Goto Y; Takagi A; Kohara M; Suga H; Harashima H
    Mol Pharm; 2017 Oct; 14(10):3290-3298. PubMed ID: 28789523
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Improved Stability of siRNA-Loaded Lipid Nanoparticles Prepared with a PEG-Monoacyl Fatty Acid Facilitates Ligand-Mediated siRNA Delivery.
    Sakurai Y; Mizumura W; Ito K; Iwasaki K; Katoh T; Goto Y; Suga H; Harashima H
    Mol Pharm; 2020 Apr; 17(4):1397-1404. PubMed ID: 32091909
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Failure of active targeting by a cholesterol-anchored ligand and improvement by altering the lipid composition to prevent ligand desorption.
    Yamamoto S; Sakurai Y; Harashima H
    Int J Pharm; 2018 Jan; 536(1):42-49. PubMed ID: 29126905
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Functional improvement of an IRQ-PEG-MEND for delivering genes to the lung.
    Ishitsuka T; Akita H; Harashima H
    J Control Release; 2011 Aug; 154(1):77-83. PubMed ID: 21619903
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Endosomal escape and the knockdown efficiency of liposomal-siRNA by the fusogenic peptide shGALA.
    Sakurai Y; Hatakeyama H; Sato Y; Akita H; Takayama K; Kobayashi S; Futaki S; Harashima H
    Biomaterials; 2011 Aug; 32(24):5733-42. PubMed ID: 21605898
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Systemic delivery of siRNA to tumors using a lipid nanoparticle containing a tumor-specific cleavable PEG-lipid.
    Hatakeyama H; Akita H; Ito E; Hayashi Y; Oishi M; Nagasaki Y; Danev R; Nagayama K; Kaji N; Kikuchi H; Baba Y; Harashima H
    Biomaterials; 2011 Jun; 32(18):4306-16. PubMed ID: 21429576
    [TBL] [Abstract][Full Text] [Related]  

  • 7. RNAi-mediated gene knockdown and anti-angiogenic therapy of RCCs using a cyclic RGD-modified liposomal-siRNA system.
    Sakurai Y; Hatakeyama H; Sato Y; Hyodo M; Akita H; Ohga N; Hida K; Harashima H
    J Control Release; 2014 Jan; 173():110-8. PubMed ID: 24120854
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Modality of tumor endothelial VEGFR2 silencing-mediated improvement in intratumoral distribution of lipid nanoparticles.
    Yamamoto S; Kato A; Sakurai Y; Hada T; Harashima H
    J Control Release; 2017 Apr; 251():1-10. PubMed ID: 28192155
    [TBL] [Abstract][Full Text] [Related]  

  • 9. pH-labile PEGylation of siRNA-loaded lipid nanoparticle improves active targeting and gene silencing activity in hepatocytes.
    Hashiba K; Sato Y; Harashima H
    J Control Release; 2017 Sep; 262():239-246. PubMed ID: 28774839
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficient short interference RNA delivery to tumor cells using a combination of octaarginine, GALA and tumor-specific, cleavable polyethylene glycol system.
    Sakurai Y; Hatakeyama H; Akita H; Oishi M; Nagasaki Y; Futaki S; Harashima H
    Biol Pharm Bull; 2009 May; 32(5):928-32. PubMed ID: 19420766
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A pH-sensitive fusogenic peptide facilitates endosomal escape and greatly enhances the gene silencing of siRNA-containing nanoparticles in vitro and in vivo.
    Hatakeyama H; Ito E; Akita H; Oishi M; Nagasaki Y; Futaki S; Harashima H
    J Control Release; 2009 Oct; 139(2):127-32. PubMed ID: 19540888
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A pH-sensitive cationic lipid facilitates the delivery of liposomal siRNA and gene silencing activity in vitro and in vivo.
    Sato Y; Hatakeyama H; Sakurai Y; Hyodo M; Akita H; Harashima H
    J Control Release; 2012 Nov; 163(3):267-76. PubMed ID: 23000694
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficient siRNA delivery and tumor accumulation mediated by ionically cross-linked folic acid-poly(ethylene glycol)-chitosan oligosaccharide lactate nanoparticles: for the potential targeted ovarian cancer gene therapy.
    Li TS; Yawata T; Honke K
    Eur J Pharm Sci; 2014 Feb; 52():48-61. PubMed ID: 24178005
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Enhanced siRNA delivery using cationic liposomes with new polyarginine-conjugated PEG-lipid.
    Kim HK; Davaa E; Myung CS; Park JS
    Int J Pharm; 2010 Jun; 392(1-2):141-7. PubMed ID: 20347025
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Chitosan-based nanoparticles for survivin targeted siRNA delivery in breast tumor therapy and preventing its metastasis.
    Sun P; Huang W; Jin M; Wang Q; Fan B; Kang L; Gao Z
    Int J Nanomedicine; 2016; 11():4931-4945. PubMed ID: 27729789
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Structure, activity and uptake mechanism of siRNA-lipid nanoparticles with an asymmetric ionizable lipid.
    Suzuki Y; Ishihara H
    Int J Pharm; 2016 Aug; 510(1):350-8. PubMed ID: 27374199
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Highly specific delivery of siRNA to hepatocytes circumvents endothelial cell-mediated lipid nanoparticle-associated toxicity leading to the safe and efficacious decrease in the hepatitis B virus.
    Sato Y; Matsui H; Yamamoto N; Sato R; Munakata T; Kohara M; Harashima H
    J Control Release; 2017 Nov; 266():216-225. PubMed ID: 28986168
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Reducing the Cytotoxicity of Lipid Nanoparticles Associated with a Fusogenic Cationic Lipid in a Natural Killer Cell Line by Introducing a Polycation-Based siRNA Core.
    Nakamura T; Yamada K; Fujiwara Y; Sato Y; Harashima H
    Mol Pharm; 2018 Jun; 15(6):2142-2150. PubMed ID: 29668291
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Gene silencing via RNAi and siRNA quantification in tumor tissue using MEND, a liposomal siRNA delivery system.
    Sakurai Y; Hatakeyama H; Sato Y; Hyodo M; Akita H; Harashima H
    Mol Ther; 2013 Jun; 21(6):1195-203. PubMed ID: 23568259
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Development of a Novel Liposomal DDS by Manipulating Pharmacokinetics and Intracellular Trafficking for Drug Therapy and Nucleic Acid Medicine].
    Hatakeyama H
    Yakugaku Zasshi; 2018; 138(5):591-598. PubMed ID: 29709998
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 31.